The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.
about
The staphylococcal enterotoxin (SE) family: SEB and siblingsStrategies for appropriate antibiotic use in intensive care unitRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsMethicillin-resistant Staphylococcus aureus therapy: past, present, and futureTreatment of Gram-positive infections in critically ill patientsCurrent concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureusComparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolidPredictors of Adverse Outcomes in Children With Staphylococcus aureus BacteremiaVancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.Vancomycin monitoring in children using bayesian estimation.Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.Vancomycin revisited - 60 years laterClinical management of Staphylococcus aureus bacteremia: a review.High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.Persistent catheter-related Staphylococcus aureus bacteremia after catheter removal and initiation of antimicrobial therapy.Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugA propensity score analysis shows that empirical treatment with linezolid does not increase the thirty-day mortality rate in patients with Gram-negative bacteremia.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort studyThe role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsInvasive gram-positive bacterial infection in cancer patients.Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates.Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure.Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.Antibiotic management of methicillin-resistant Staphylococcus aureus--associated acute pulmonary exacerbations in cystic fibrosis.Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.agr dysfunction affects staphylococcal cassette chromosome mec type-dependent clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Methicillin-resistant Staphylococcus aureus mandibular osteomyelitis in an extremely low birth weight preterm infantIdentification of Low-Level Vancomycin Resistance in Staphylococcus aureus in the Era of InformaticsPersistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates.Complete genome of Staphylococcus aureus phage SA11.Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia.Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings.Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?
P2860
Q26830220-5D07A088-89BA-455C-B202-AFD7D43F8352Q27002517-B3D93DCA-D7CA-4C97-BB39-91B658CDCB89Q27011138-54C7AB7F-988E-4949-83AB-F74DC5B65836Q27011165-D69A0580-1CB9-443E-A655-C2228EEDE84DQ27015976-087698BB-3C1F-4528-8890-1F046D3E8BEEQ27023330-EBDDA448-FA41-469B-ACB0-242BC8D6DD39Q33703519-83D57FD4-B636-4925-AC01-CBC127408809Q33806504-8060A1FA-15E2-47FA-BE04-213568478EE8Q33844670-FD320BB2-FE77-45A0-B56B-BB2FAF5B4A9FQ33911485-9C2419C2-A761-4383-9662-6C9681D4A84BQ34058222-D8EE4017-A102-478A-AD8D-8A922117FB2BQ34433066-2060EB3F-C5FC-4C74-8870-28C318912BCEQ34441035-25840C7F-92C3-4DB1-88AE-F0E4CD882C15Q34454418-FC2DDF8C-81A9-44A4-AC7F-4FAAFD4609D7Q34463444-2F2256AC-7E36-4B3B-A021-4430C4EBAD18Q34548251-6244F6DE-38AB-44ED-96E2-9811225278ACQ34597369-AF436CE1-2C0A-43B6-9DD5-54D7F88FE849Q34636783-9C980F27-2D2A-4F1A-93C5-D8F69914C630Q34672655-B639A3B0-E3C8-42B3-876D-35C98A5A8031Q34967980-6E73CD41-E591-4A73-9E77-7A9DEE7C18C4Q34999500-DF14CD6B-0980-4EC5-B353-FC2D77B6C44BQ34999884-69D63019-4E9A-4E14-8217-742FAD1AF1E9Q35035799-545391F4-9654-41DA-AEF4-720A9976852AQ35038242-98458961-EAF5-47D2-AED3-4A6BE3A46A03Q35064413-752FD5AD-6D84-4350-B0B8-4301AB532462Q35179800-B798AD2C-7EE3-48EC-B790-47E15A0A9B86Q35542062-63A3E5AE-9A42-4840-817F-88E8CC7A2C29Q35607636-410D194A-60BC-4926-88FC-397F1BC2647BQ35607900-84454945-03D1-4DC9-887F-475066AF9F31Q35607912-A3CF7C70-BD0B-4B7B-BCB4-2F6A585B387AQ35619094-EA86A07C-3C98-411F-9C2C-18B1D9F852AEQ35752011-B31A16F3-270F-49E4-BDDA-B472667DB4CFQ35913474-D995FCD6-FD3D-4588-83D4-89ACE81DF963Q35920382-0F5492AE-59DE-4BFB-B502-CD464D1CE20AQ36008997-E2EA5D28-63ED-4E02-A8EA-A72D82868FD2Q36246292-B9A26716-BFDC-41A9-AFD9-752827DE4B15Q36276932-0B6C6610-1C40-4564-9BA5-39FDBC7C37DEQ36478309-49CA6F9B-B8AE-4899-87A1-5E521D7EC9EBQ36757645-B8B20CB2-6393-48DE-8A15-E6CC816D8BEDQ36856946-AB73522F-9371-4770-8862-F7B1BA7655B0
P2860
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The clinical significance of v ...... atic review and meta-analysis.
@en
The clinical significance of v ...... atic review and meta-analysis.
@nl
type
label
The clinical significance of v ...... atic review and meta-analysis.
@en
The clinical significance of v ...... atic review and meta-analysis.
@nl
prefLabel
The clinical significance of v ...... atic review and meta-analysis.
@en
The clinical significance of v ...... atic review and meta-analysis.
@nl
P2860
P356
P1476
The clinical significance of v ...... matic review and meta-analysis
@en
P2093
S J van Hal
T P Lodise
P2860
P304
P356
10.1093/CID/CIR935
P407
P577
2012-02-02T00:00:00Z